APD-403 is under clinical development by Acacia Pharma and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect APD-403’s likelihood of approval (LoA) and phase transition for Chemotherapy Induced Nausea and Vomiting took place on 12 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their APD-403 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
APD-403 (amisulpride) is under development for the prevention of acute and delayed chemotherapy induced nausea and vomiting (CINV). The drug candidate is administered through intravenous and oral routes and formulated as tablet to prevent delayed CINV. The drug candidate is a small molecule and acts by targeting dopamine D2 and D3-receptor. APD-403 is the sister product of APD-421. It is a repurposed dug.
Acacia Pharma overview
Acacia Pharma a subsidiary of Acacia Pharma Group PLC, is a pharmaceutical company focused on the development and commercialization of hospital nausea and vomiting products for surgical and cancer patients. Its pipeline products include barhemsys, formerly APD421 is an intravenous formulation of amisulpride, a selective dopamine antagonist used for the treatment and prophylaxis of post-operative nausea and vomiting (PONV); APD403 an intravenous injection for cancer patients to prevent acute chemotherapy-induced nausea & vomiting (CINV) and Byfavo. The company serves transforming medicine, advancing care, and pharmaceutical sectors. It also establishes licensing and distribution agreements with pharmaceutical partners outside the US. Acacia is headquartered in Cambridge, England, the UK.
Quick View APD-403 LOA Data
|Highest Development Stage|